Effect of HIV on bedaquiline and delamanid pharmacokinetics in patients with multidrug-resistant TB
The International Journal of Tuberculosis and Lung Disease · 2025
DOI: 10.5588/ijtld.24.0637 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The International Journal of Tuberculosis and Lung Disease, 2025. Verfasst von J Shenje und 7 weiteren Autor:innen. Beteiligte Einrichtung: South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Diarylquinolines, Nitroimidazoles, Antitubercular Agents, Oxazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
BACKGROUND
Bedaquiline and delamanid are key drugs in the treatment of multidrug-resistant TB. It is unclear whether HIV affects the pharmacokinetics of bedaquiline and delamanid.
METHODS
Participants with multidrug-resistant TB were randomised to treatment with bedaquiline, delamanid, or both, plus a standard-of-care treatment. Intensive pharmacokinetic sampling was performed after 8 weeks of therapy. We performed non-compartment analysis to describe bedaquiline and delamanid pharmacokinetics, comparing exposures between HIV-positive and HIV-negative participants using geometric mean ratios (GMRs), and explored covariates associated with bedaquiline and delamanid AUC, using multivariable regression modelling.
RESULTS
Twenty-six participants were assigned to bedaquiline, 25 received delamanid, and 24 received both drugs. Fifty and 49 participants were treated with bedaquiline and delamanid, respectively. The GMR (90% confidence interval [CI]) of bedaquiline AUC 0–22 and C max in HIV-positive compared with HIV-negative participants was 0.76 (0.61–0.94) and 0.94 (0.78–1.06), respectively. The GMR (90% CI) of delamanid AUC 0–23 and C max in HIV-positive compared with HIV-negative participants was 0.93 (0.79–1.09) and 0.79 (0.49–1.27), respectively.
CONCLUSION
HIV infection was associated with a 24% reduction in bedaquiline AUC 0–22 , the significance of which requires further exploration. Delamanid exposure was unaffected by HIV status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa.
- Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
- Social and Scientific Systems, A DLH Company, Silver Spring, MD, USA.
- Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- Asociacion Civil Impacta Salud y Educacion, Lima, Peru.
- TASK, Cape Town, South Africa.
Förderung
- NIAID NIH HHS
Zitieren
APA
Shenje, J., Maartens, G., Moran, L., Cramer, Y., Rios, J. D. L., Diacon, A., Dooley, K., & Court, R. (2025). Effect of HIV on bedaquiline and delamanid pharmacokinetics in patients with multidrug-resistant TB. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.24.0637
Vancouver
Shenje J, Maartens G, Moran L, Cramer Y, Rios JDL, Diacon A, et al. Effect of HIV on bedaquiline and delamanid pharmacokinetics in patients with multidrug-resistant TB. The International Journal of Tuberculosis and Lung Disease. 2025. doi:10.5588/ijtld.24.0637
BibTeX
@article{Shenje2025,
author = {Shenje, J and Maartens, G and Moran, L and Cramer, Y and Rios, J D L and Diacon, A and Dooley, K and Court, R},
title = {Effect of HIV on bedaquiline and delamanid pharmacokinetics in patients with multidrug-resistant TB},
journal = {The International Journal of Tuberculosis and Lung Disease},
year = {2025},
doi = {10.5588/ijtld.24.0637}
}
EUVIMED